FDA advisory panel votes in favor of NovoTTF-100A System for supra-tentorial glioblastoma multiforme tumors

Novocure announced today that the U.S. Food and Drug Administration (FDA) Neurological Devices Advisory Panel of the Medical Devices Advisory Committee voted (7 yes; 3 no; 2 abstain) that for patients with supra-tentorial glioblastoma multiforme (GBM) tumors that recur after maximal surgical and radiation treatments, there is reasonable assurance that the benefits of the NovoTTF-100A System (NovoTTF) outweigh its risks when administered as a monotherapy in place of standard medical therapy.  

"We are pleased with the outcome of the Advisory Committee's vote on the safety and effectiveness of NovoTTF," said Eilon Kirson, M.D., Ph.D., and the Chief Medical Officer of Novocure.  

The committee's recommendation followed a review of data from the EF-11 Trial, a randomized phase III trial for 237 patients with glioblastoma tumors that had recurred or progressed despite previous treatments.   The committee received and considered the final data from the EF-11 Trial, which updated data previously reported at the American Society for Clinical Oncology Annual Meeting in June 2010.   The trial demonstrated that patients treated with the NovoTTF alone achieved a comparable overall survival time to patients treated with the physician's choice of the best chemotherapy.  Patients treated with the NovoTTF also had higher rates of progression free survival at six months (PFS6) and higher tumor response rates (RR) compared to chemotherapy treated patients in the trial (PFS6 of 21 percent vs. 15 percent and RR of 14 percent vs. 10 percent).  NovoTTF treated patients reported better quality of life scores and fewer side effects during the trial compared to patients treated with chemotherapy.  The NovoTTF's most commonly reported side effect was a mild-to-moderate rash beneath the electrodes.

"We look forward to working with the FDA to bring this novel, important therapy to patients as soon as possible," said Asaf Danziger, CEO of Novocure.  The FDA is currently reviewing a pre-market approval (PMA) application for the NovoTTF for this indication.